Our findings suggest that tumor-specific CD8+ T cells need to ideally be present and activated prior to RPT for greater anti-tumor efficacy, suggesting that anti-tumor vaccination should be delivered prior to RPT [162]. Here, CD8A is linked to neoplasm.